BIIB
Biogen Inc
Biogen Inc historical holders
total: 12
Hillman Value Fund Biogen Inc transactions over time
- Total transactions:
- 12
- New positions:
- 1
- Added:
- 6
- Reduced:
- 5
- Held since:
- 2020 Q1
- Held for:
- 25 quarters
- Latest activity:
- 2025 Q4
Mark A. Hillman has been an institutional investor in Biogen Inc (BIIB) since 2020 Q1. According to 2026 Q1 report, Mark A. Hillman holds 14,100 shares with a market value of roughly $2.58M representing 3.11% of their equity portfolio. The fund/company first acquired BIIB in 2020 Q1, initially purchasing 10,000 shares. Since the initial investment, Hillman Value Fund has made 11 more transactions in this position.
Does Mark A. Hillman still hold BIIB?
Yes, Mark A. Hillman continues to hold Biogen Inc (BIIB). According to their 2026 Q1 report, they maintain a position of 14,100 shares valued at approximately $2.58M, representing 3.11% of their equity portfolio.
When did Mark A. Hillman first invest in BIIB?
Mark A. Hillman first invested in Biogen Inc (BIIB) in 2020 Q1 at the reported quarter-end price of $316.38 per share, acquiring 10,000 shares in their initial purchase.
What is Mark A. Hillman's average cost basis for BIIB?
Based on historical transaction data, Mark A. Hillman's estimated cost basis for Biogen Inc (BIIB) is approximately $243.00 per share. This represents their average reported price* across all buy transactions.
Estimated cost basis*
- Weighted AVG buy price:
- $243.00
- Weighted AVG sell price:
- $191.00
BIIB transactions history by Hillman Value Fund
12 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2025 Q4
|
2.65%
|
14,100
|
$175.99
|
$2,481,459
|
-27.69% (-5,400)
|
-0.9%
|
|
2025 Q3
|
2.60%
|
19,500
|
$140.08
|
$2,731,560
|
-17.37% (-4,100)
|
-0.48%
|
|
2025 Q2
|
2.50%
|
23,600
|
$125.59
|
$2,963,924
|
-8.53% (-2,200)
|
-0.19%
|
|
2025 Q1
|
2.48%
|
25,800
|
$136.84
|
$3,530,472
|
-21.82% (-7,200)
|
-0.47%
|
|
2024 Q4
|
2.39%
|
33,000
|
$152.92
|
$5,046,360
|
+35.25% (+8,600)
|
+0.62%
|
|
2024 Q1
|
2.17%
|
24,400
|
$215.63
|
$5,261,372
|
+0.57% (+139)
|
+0.01%
|
|
2023 Q3
|
2.99%
|
24,261
|
$257.01
|
$6,235,320
|
+32.86% (+6,000)
|
+0.74%
|
|
2022 Q3
|
2.71%
|
18,261
|
$267.00
|
$4,875,687
|
-37.25% (-10,839)
|
-1.39%
|
|
2022 Q1
|
2.49%
|
29,100
|
$210.60
|
$6,128,460
|
+59.89% (+10,900)
|
+0.93%
|
|
2021 Q1
|
2.95%
|
18,200
|
$279.75
|
$5,091,450
|
+37.88% (+5,000)
|
+0.81%
|
|
2020 Q3
|
3.61%
|
$283.68
|
+32.00% (+3,200)
|
|||
|
2020 Q1
|
4.41%
|
$316.38
|
new
|
|||
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.